Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

Registrati

Quotazioni in diretta

CORT Corcept Therapeutics Inc

61,00

1,15 (1,92%)

01 Mar 2025 - Chiuso

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Joseph Douglas Lyon and Jd Lyon are one and the same person.

Date of Notice

11/22/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Jared Cook, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jd Lyon

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Corcept Therapeutics (NASDAQ:CORT)
Storico
Da Feb 2025 a Mar 2025

Clicca qui per i Grafici di Corcept Therapeutics

Grafico Azioni Corcept Therapeutics (NASDAQ:CORT)
Storico
Da Mar 2024 a Mar 2025

Clicca qui per i Grafici di Corcept Therapeutics

Notizie Corcept Therapeutics Inc - CORT

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mercoledì 26 Febbraio 2025 (3 giorni fa) • Edgar (US Regulatory)

Form 8-K - Current report
Mercoledì 26 Febbraio 2025 (3 giorni fa) • Edgar (US Regulatory)

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
Mercoledì 26 Febbraio 2025 (3 giorni fa) • Business Wire

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Sabatp 15 Febbraio 2025 (2 settimane fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 14 Febbraio 2025 (2 settimane fa) • Edgar (US Regulatory)

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
Mercoledì 12 Febbraio 2025 (2 settimane fa) • Business Wire

Form 144 - Report of proposed sale of securities
Lunedì 10 Febbraio 2025 (3 settimane fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 5 Febbraio 2025 (3 settimane fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 5 Febbraio 2025 (3 settimane fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Lunedì 3 Febbraio 2025 (4 settimane fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Lunedì 3 Febbraio 2025 (4 settimane fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Sabatp 25 Gennaio 2025 (1 mese fa) • Edgar (US Regulatory)

Più Corcept Therapeutics Inc Articoli Notizie

BNP Paribas Issuance

Societe Generale Effekten

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea